Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Neutropenic Fever During Stem Cell Mobilization Is Associated with Decreased CD34+ Cell Collection and Poor Survival Following Autologous Stem Cell Transplantation,

Hien Duong, MD, Brian J. Bolwell, MD, Lisa Rybicki, MS, John William Sweetenham, MD, Brad Pohlman, MD, Robert Dean, MD, Steven Andresen, DO, Matt Kalaycio, MD, Ronald Sobecks, MD, Anna Koo, MD, Edward A. Copelan, MD

Blood (2011) 118 (21): 4053.

https://doi.org/10.1182/blood.V118.21.4053.4053

Published: 2011

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

Nina Wagner-Johnston, Andre Goy, MD, Tatyana Feldman, MD, Yeow Tee Goh, MD, Cheolwon Suh, MD, John William Sweetenham, MD, FRCP, Christine Powell, Sharon T. Sullivan, PhD, Erik R. Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2010) 116 (21): 2883.

https://doi.org/10.1182/blood.V116.21.2883.2883

Published: 2010

Journal Articles

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Aleksandr Lazaryan, MD, MPH, PhD, Rachid Baz, MD, Mohamad A Hussein, Jr, MD, Paul Elson, ScD, Beth Faiman, CNP, Becky Habecker, Mary Ann Karam, RN, Janice Reed, RN, Kimberly Hamilton, RN, Kellie Bruening, Gordan Srkalovic, MD, PhD, Steven Andresen, DO, Matt Kalaycio, MD, John William Sweetenham, MD, FRCP, Ronald Sobecks, MD, Robert Dean, MD, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Frederic J. Reu, MD

Blood (2010) 116 (21): 1967.

https://doi.org/10.1182/blood.V116.21.1967.1967

Published: 2010

Journal Articles

Higher Non-Relapse Mortality with BuCyVP Compared to BuCy In Allogeneic Hematopoietic Stem Cell Transplant

Hien Duong, MD, Brian J. Bolwell, MD, Lisa Rybicki, MS, Matt Kalaycio, MD, Steven Andresen, DO, Ronald Sobecks, MD, Robert Dean, MD, John William Sweetenham, MD, FRCP, Shawnda Tench, Edward A. Copelan, MD

Blood (2010) 116 (21): 1340.

https://doi.org/10.1182/blood.V116.21.1340.1340

Published: 2010

Journal Articles

Analysis of Readmission After Autologous HCT: Predictive Factors and Clinical Consequences

Sanjay R. Mohan, MD, Lisa Rybicki, MS, Stephen D. Smith, MD, Robert Dean, MD, Brad Pohlman, MD, John William Sweetenham, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Steven Andresen, DO, Edward A. Copelan, MD, Brian J. Bolwell, MD

Blood (2010) 116 (21): 932.

https://doi.org/10.1182/blood.V116.21.932.932

Published: 2010

Journal Articles

Intrathecal Chemotherapy Prophylaxis for CNS Relapse of DLBCL In the RCHOP Era: A Single Center Analysis.

Christopher Scott Kovacs, Jr., MD, John William Sweetenham, MD, FRCP, Marc Earl, Pharm., D., R.Ph., Robert Dean, MD, Brad Pohlman, MD, Brian Bolwell, MD, Stephen D. Smith, MD, BS

Blood (2010) 116 (21): 2804.

https://doi.org/10.1182/blood.V116.21.2804.2804

Published: 2010

Journal Articles

Validation of the Mantle Cell Lymphoma Prognostic Index (MIPI): A Valuable Tool for Risk Stratification in Mantle Cell Lymphoma.

Stephen Douglas Smith, MD, Eric D. Hsi, MD, Brian J. Bolwell, Amanda Maggiotto, B.S., Meagan Effinger, B.A., John William Sweetenham, MD

Blood (2009) 114 (22): 2703.

https://doi.org/10.1182/blood.V114.22.2703.2703

Published: 2009

Journal Articles

Birth Order Does Not Affect Outcome in HLA-Identical Sibling Transplantation.

Edward Copelan, MD, Ronald Sobecks, MD, Robert Dean, MD, Lisa Rybicki, Stacey Brown, Matt Kalaycio, MD, Brad Pohlman, MD, John William Sweetenham, MD, Steven Andresen, DO, Brian Bolwell, MD

Blood (2007) 110 (11): 5003.

https://doi.org/10.1182/blood.V110.11.5003.5003

Published: 2007

Journal Articles

Disappointing Outcomes of Peripheral T Cell Lymphoma after Autologous Stem Cell Transplantation.

Stephen D. Smith, MD, John William Sweetenham, MD, Lisa Rybicki, MS, Stacey Brown, BA, Robert M. Dean, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Steve Andresen, DO, Eric His, MD, Brad Pohlman, MD, Brian J. Bolwell, MD

Blood (2006) 108 (11): 5428.

https://doi.org/10.1182/blood.V108.11.5428.5428

Published: 2006

Journal Articles

Comparison of T Cell (CD3+) Chimerism after Myeloablative (MY) and Nonmyeloablative (NM) Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

Ronald Sobecks, MD, Karl Theil, MD, Lisa Rybicki, MS, Jennifer Bates, BS, Matt Kalaycio, MD, Steven Andresen, DO, Brad Pohlman, MD, Robert M. Dean, MD, John William Sweetenham, MD, Laura Bernhard, RN, Kelly Cherni, RN, Mary Serafin, RN, Karen Sands, RN, Jennifer Kosar, RN, Brian J. Bolwell, MD

Blood (2006) 108 (11): 2960.

https://doi.org/10.1182/blood.V108.11.2960.2960

Published: 2006

Journal Articles

Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).

Ronald Sobecks, MD, Edward J. Ball, PhD, Medhat Askar, MD, PhD., Karl Theil, MD, Lisa Rybicki, MS, Dawn Thomas, CHS, Jennifer Bates, BS, Matt Kalaycio, MD, Steven Andresen, DO, Brad Pohlman, MD, Robert M. Dean, MD, John William Sweetenham, MD, Laura Bernhard, RN, Kelly Cherni, RN, Jaroslaw P. Maciejewski, MD, MS, Brian J. Bolwell, MD

Blood (2006) 108 (11): 3012.

https://doi.org/10.1182/blood.V108.11.3012.3012

Published: 2006

Journal Articles

Patients Mobilizing Large Numbers of CD34+ Cells ("Super-Mobilizers") Have Improved Survival in Autologous Stem Cell Transplantation for Lymphoid Malignancies.

Brian J. Bolwell, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Robert M. Dean, MD, Laura Bernhard, RN, Kelly Cherni, RN, Christina Ferraro, RN, Jenny Bates, Stacey Brown, John William Sweetenham, MD

Blood (2006) 108 (11): 3378.

https://doi.org/10.1182/blood.V108.11.3378.3378

Published: 2006

Journal Articles

Prior Therapy with Rituximab (R) in Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Does Not Affect Disease-Free (DFS) or Overall Survival (OS) Following High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT).

Snehal G. Thakkar, MD, John William Sweetenham, MD, Lisa Rybicki, Ronald Sobecks, MD, Steven Andresen, DO, Robert M. Dean, MD, Brad Pohlman, MD, Tyler Y. Kang, MD, Matt Kalaycio, MD, Stacey Brown, Brian J. Bolwell, MD

Blood (2006) 108 (11): 3054.

https://doi.org/10.1182/blood.V108.11.3054.3054

Published: 2006

Journal Articles

Prior Therapy with Rituximab (R) in Patients with Follicular Lymphoma (FL) Does Not Affect Relapse-Free (RFS) or Overall Survival (OS) after High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT).

Tyler Y. Kang, MD, John William Sweetenham, MD, Snehal G. Thakkar, MD, Lisa A. Rybicki, MS, Stacey Brown, Robert Dean, MD, Mikkael A. Sekeres, MD, MS, Anjali Advani, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Brad Pohlman, MD, Brian J. Bolwell, MD

Blood (2006) 108 (11): 3069.

https://doi.org/10.1182/blood.V108.11.3069.3069

Published: 2006

Journal Articles

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Therapy with Rituximab Maintenance in Patients with Untreated Low-Grade Follicular Lymphoma.

John William Sweetenham, MD, Karel Dicke, MD, PHD, John Arcaroli, Karen Kogel, MD, Tahir M. Rana, MD, Laura L. Rice, BSMT, CLSp(CG), CCRP

Blood (2004) 104 (11): 2633.

https://doi.org/10.1182/blood.V104.11.2633.2633

Published: 2004

Journal Articles

Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.

Peter Johnson, MD, Peter Hoskin, MD, Alan Horwich, MD, Barry Hancock, MD, Paul Smith, Lindsey Stevens, Wendy Qian, John William Sweetenham, MD

Blood (2004) 104 (11): 311.

https://doi.org/10.1182/blood.V104.11.311.311

Published: 2004

NARROW

Neutropenic Fever During Stem Cell Mobilization Is Associated with Decreased CD34+ Cell Collection and Poor Survival Following Autologous Stem Cell Transplantation,

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Higher Non-Relapse Mortality with BuCyVP Compared to BuCy In Allogeneic Hematopoietic Stem Cell Transplant

Analysis of Readmission After Autologous HCT: Predictive Factors and Clinical Consequences

Intrathecal Chemotherapy Prophylaxis for CNS Relapse of DLBCL In the RCHOP Era: A Single Center Analysis.

Validation of the Mantle Cell Lymphoma Prognostic Index (MIPI): A Valuable Tool for Risk Stratification in Mantle Cell Lymphoma.

Birth Order Does Not Affect Outcome in HLA-Identical Sibling Transplantation.

Disappointing Outcomes of Peripheral T Cell Lymphoma after Autologous Stem Cell Transplantation.

Comparison of T Cell (CD3+) Chimerism after Myeloablative (MY) and Nonmyeloablative (NM) Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).

Patients Mobilizing Large Numbers of CD34+ Cells ("Super-Mobilizers") Have Improved Survival in Autologous Stem Cell Transplantation for Lymphoid Malignancies.

Prior Therapy with Rituximab (R) in Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Does Not Affect Disease-Free (DFS) or Overall Survival (OS) Following High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT).

Prior Therapy with Rituximab (R) in Patients with Follicular Lymphoma (FL) Does Not Affect Relapse-Free (RFS) or Overall Survival (OS) after High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT).

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Therapy with Rituximab Maintenance in Patients with Untreated Low-Grade Follicular Lymphoma.

Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only